p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma

Lindi Chen1, Nunzio Iraci3, Samuele Gherardi3, Laura D. Gamble1, Katrina M. Wood2, Giovanni Perini3, John Lunec1, and Deborah A. Tweddle1

Abstract

MYCN amplification occurs in ~25% of neuroblastomas, where it is associated with rapid tumor progression and poor prognosis. MYCN plays a paradoxical role in driving cellular proliferation and inducing apoptosis. Based on observations of high p53 accumulation in neuroblastomas, we hypothesized that MYCN may regulate p53 in this setting. Immunohistochemical analysis of 82 neuroblastoma tumors showed an association of high p53 expression with MYCN expression and amplification. In a panel of 5 MYCN-amplified and 5 nonamplified neuroblastoma cell lines, and also in the Tet21N-regulatable MYCN expression system, we further documented a correlation between the expression of MYCN and p53. In MYCN-amplified neuroblastoma cell lines, MYCN knockdown decreased p53 expression. In Tet21N MYCN+ cells, higher levels of p53 transcription, mRNA, and protein were observed relative to Tet21N MYCN- cells. In chromatin immunoprecipitation and reporter gene assays, MYCN bound directly to a Myc E-Box DNA binding motif located close to the transcriptional start site within the p53 promoter, where it could initiate transcription. E-Box mutation decreased MYCN-driven transcriptional activation. Microarray analysis of Tet21N MYCN+/- cells identified several p53-regulated genes that were upregulated in the presence of MYCN, including MDM2 and PUMA, the levels of which were reduced by MYCN knockdown. We concluded that MYCN transcriptionally upregulates p53 in neuroblastoma and uses p53 to mediate a key mechanism of apoptosis.

Introduction

Neuroblastoma is an embryonal malignancy derived from precursor cells of the sympathetic nervous system. Despite significant advances in understanding the biology of this tumor, it currently still remains one of the most difficult childhood cancers to cure, with <40% of patients with high risk disease (stage 4 disease over 18 months of age or MYCN-amplified disease) being long-term survivors (1, 2).

Amplification of MYCN occurs in ~25% of neuroblastomas, and is associated with rapid tumor progression and poor prognosis (reviewed in ref. 3). MYCN belongs to the Myc family of basic-helix-loop-helix-leucine zipper transcription factors that have a critical role in cellular proliferation, differentiation, apoptosis, and oncogenesis. Members of this family function as heterodimers with Max, and exert transcriptional activity by specifically binding to consensus E-Box motifs (CA(C/T)GTG) located within the promoter regions of a diverse set of target genes (reviewed in ref. 4). In contrast to c-MYC, which is expressed in a wide variety of embryonic and adult tissues, MYCN expression is limited to the developing nervous system and selected other sites.

Several genes have been identified as c-MYC transcriptional targets (5), however, less is known about target genes of MYCN. Early studies found that several c-MYC target genes were expressed in some neuroblastoma cell lines with MYCN amplification, but not all, suggesting that other cell-specific factors may be important (6). Recent studies have reported significant overlap between c-MYC and MYCN-regulated gene sets (7, 8). Enhanced ectopic expression of MYCN leads to both accelerated cell cycle progression and sensitization to apoptosis, therefore, mechanisms which minimize or evade MYCN-driven apoptosis are essential for tumor progression in neuroblastomas with MYCN amplification (reviewed in ref. 9).

p53, often referred to as the “guardian of the genome”, is mutated in up to 60% of many human malignancies. In neuroblastoma, p53 is rarely mutated, however, protein accumulation is frequently observed in both neuroblastoma tumors

Authors’ Affiliations:
1 Northern Institute for Cancer Research, Newcastle University, Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom; and 2 Department of Biology, University of Bologna, Bologna, Italy

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Corresponding Author: Deborah A. Tweddle, Newcastle University, Northern Institute for Cancer Research, Paul O’Gorman Building, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, United Kingdom; Phone: 44-191-246-4421; Fax: 44-191-246-4301; E-mail: D.A.Tweddle@newcastle.ac.uk.

doi: 10.1158/0008-5472.CAN-09-2598 ©2010 American Association for Cancer Research.

http://www.myc-cancer-gene.org/site/mycTargetDB.asp
and cell lines (reviewed in ref. 10). The presence of accumulated p53 in neuroblastoma has been suggested to be due to the embryonic nature of these tumors, reflecting a failure of the precursor cells to mature (11). We and others have shown that the accumulated p53 is both predominantly nuclear and functional in neuroblastoma tumors and cell lines (reviewed in ref. 12).

Early studies using reporter gene assays and electrophoretic gel mobility analysis reported that p53 was a direct target gene of c-MYC (13, 14). Furthermore, it was shown using

![Image of immunohistochemistry](https://example.com/image.png)

Figure 1. p53 expression is associated with MYCN amplification and MYCN protein expression in untreated neuroblastoma tumors. A, top, immunohistochemistry of a stroma-poor, undifferentiated, MYCN-amplified, stage 4 primary neuroblastoma, using p53DO-7 antibody (left) showing heterogeneous nuclear immunostaining, absent in apoptotic cells (arrow) and MYCN antibody (right) showing heterogeneous nuclear immunostaining with negative stroma and negative mitotic and apoptotic cells (arrows). Bottom, immunohistochemistry of a stroma-poor nodule of a non–MYCN-amplified, stage 4 primary nodular ganglioneuroblastoma, using p53DO-7 antibody (left) showing low-level nuclear immunostaining and MYCN antibody (right) showing absent immunostaining and a mitotic cell (arrow). Top right, labeling indices (LI) for antibodies. Scale bar, 50 μm. B and C, scatter plots of labeling indices showing median expression (two-tailed Mann-Whitney tests used) MYCN amplification versus MYCN (B) labeling index, and MYCN amplification versus p53DO-7 (C) labeling index (median difference shown and 95% confidence interval). D, correlation between p53DO-7 labeling index and MYCN labeling index (Spearman correlation and 95% confidence interval).
Table 1. MYCN amplification and expression is associated with p53 protein expression in 82 neuroblastomas

<table>
<thead>
<tr>
<th>Median LI, % (range)</th>
<th>MYCN (n = 82)</th>
<th>P</th>
<th>MNA* (n = 40)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>MYCN &gt;0 (0−100)</td>
<td>−</td>
<td>+</td>
<td>0</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td></td>
<td>11</td>
<td>3</td>
</tr>
<tr>
<td>p53 DO−7 8 (0−75)</td>
<td>−35</td>
<td>6</td>
<td>&lt;0.001</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>+17</td>
<td>24</td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>p53 DO−1 7 (0−89)</td>
<td>−34</td>
<td>5</td>
<td>&lt;0.001</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>+17</td>
<td>25</td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>p53 1801 2 (0−20)</td>
<td>−38</td>
<td>10</td>
<td>&lt;0.001</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>+14</td>
<td>20</td>
<td></td>
<td>9</td>
</tr>
</tbody>
</table>

*Fisher’s exact, two-sided test. All other parameters χ² used. MNA = MYCN amplification. The median labeling index (LI) for all 82 tumors was used as a cutoff for positive and negative expression (range).

quipable fibroblasts that p53 directly mediates c-MYC–induced apoptosis, and suggests that c-MYC–driven p53-mediated apoptosis acts as a safeguard mechanism against aberrant oncogenic activation (15). The p53 promoter contains a noncanonical E-Box (CATGTG) located upstream of the transcription initiation site (13, 14) and is recognized by MYC-MAX heterodimers (16), which can bind and initiate transcription (14). Several studies have reported a positive correlation between c-MYC expression and p53 expression in both cell lines and tumors, and that inhibition of c-MYC expression using either antisense RNA or inhibitory peptides led to a decrease in p53 expression (reviewed in ref. 17).

This study set out to test the hypothesis that p53 accumulation in neuroblastoma correlates with MYCN amplification status and MYCN expression, and that p53 is a direct transcriptional target of MYCN.

Materials and Methods

**Immunohistochemistry of neuroblastoma tumors.** Eighty-two formalin-fixed, paraffin-embedded diagnostic, untreated neuroblastoma tumors were examined for p53 and MYCN by immunohistochemistry using antibodies and methods previously reported (12). MYCN hybridoma supernatant MYCN (NCMIX102) was used at a 1:4 dilution. Positive tissue controls included colonic adenocarcinoma for p53 and MYCN-amplified NGP neuroblastoma cell cytoblocks for MYCN. Negative controls included incubations without primary antibodies and surrounding nontumor tissue. The p53 and MYCN labeling indices were performed as previously described (12). MYCN amplification was performed routinely on 40 frozen tumors, which were diagnosed after 1990, using Southern blot hybridization and fluorescent *in situ* hybridization.

**Cell lines.** p53 wild-type neuroblastoma cell lines (18, 19) used were MYCN-amplified (IMR32, NBLW, CHLA136, LAN5, SMSKCNR, and NGP), non–MYCN-amplified (SHSY5Y, NB69, SKNRA, and SHEP), non–MYCN-amplified high MYCN expressing (SJNB1 and NBL5), and the conditional MYCN-expressing SHEP Tet21N system together with p53-null osteosarcoma SAOS2 and p53 mutant neuroblastoma SKNB2C cells (20). Cells were cultured as previously described (21). To switch off MYCN expression, Tet21N cells were cultured in the presence of 1 μg/mL of tetracycline (Sigma) for 48 h. Cell lines were obtained from the Children’s Oncology Group Cell Culture and Xenograft Repository (LAN5), Sue Cohn (NBLW and NBL5), Linda Harris (SJNB1), Penny Lovat (SHSY5Y, SHEP, and IMR32), John Maris (NB69), Patrick Reynolds (SKNRA, SMSKCNR, and CHLA136), Barbara Spengler (SKNB2C), Manfred Schwab (SHEP Tet21N), Rogier Versteeg (NGP), and Ximena Montano (SAOS2) between 1996 and 2007, and were validated upon receipt using cytogenetic analysis courtesy of Nick Bown, Institute of Human Genetics, Newcastle University, Framlington Place, Newcastle upon Tyne, United Kingdom.

**Quantitative reverse transcription PCR.** Quantitative reverse transcription PCR (qRT-PCR) was performed as previously described (21). All primers and probes were inventoried TaqMan Gene Expression Assays (Applied Biosystems). RNA expression values were normalized to actin. All experiments were performed in triplicate.

**Western analysis.** Western blotting was performed using previously described methods (20). Primary antibodies used were p53 DO−7 (Novocastra Laboratories, Ltd.) at 1:1,000, MYCN (NCMI100) at 1:100, actin (Sigma) at 1:500, MDM2 (Calbiochem) at 1:100, p21WAF1 (Calbiochem) at 1:1,000, phosphorylated p53 (Ser15) at 1:1,000, cleaved caspase-3 (Cell Signaling Technology, Inc.) at 1:1,000, and PUMA (Calbiochem) at 1:300.

Secondary goat anti-mouse/rabbit horseradish peroxidase–conjugated antibody (Dako) was used at 1:500. Densitometry was performed as previously described (21) and expression normalized to actin.

**Plasmids and luciferase assays.** Plasmids used were the p53-dependent pGL3-P2 reporter construct (22),...
pCMV-β-galactosidase (Stratagene), pRenilla-TK vector (Promega), and p53 promoter reporter constructs pGL2-200 bp and pGL2-356 bp originally described by Wang and El-Deiry (23) and purchased from Addgene (Addgene). pGL2-Δ200 bp and pGL2-Δ356 bp were generated by replacing the E-Box CATGTG with CTGCAG, and confirmed by sequencing. The pCMV14-MYCN expression plasmid was generated by cloning the CDS of MYCN into the p3XFLAG-CMV-14 vector (Sigma). Cells were transfected using FuGENE 6 (Roche) or polyethyleneimine (Sigma). Luciferase activity was measured as previously described (24) or by using the Dual-Luciferase Reporter Assay (Promega). To control for transfection efficiency, luciferase activity was normalized to β-galactosidase activity or Renilla luciferase activity. All experiments were performed in triplicate.

**p53 DNA binding assay.** The TransAM ELISA-based p53 transcription factor assay (Active Motif) was used according to the protocols of the manufacturer. Nuclear extracts were prepared using previously described methods (12), and 5 μg of protein used per well. Samples were prepared in triplicate and assayed in duplicate. Absorption was read at 450 nm with a reference wavelength of 655 nm.

**Gene expression microarray.** Cells were harvested from Tet21N MYCN− and Tet21N MYCN+ cells in triplicate and analyzed using Affymetrix U133 plus 2.0 oligonucleotide arrays. Arrays were performed at the CRUK Facility (Paterson Institute, Manchester, United Kingdom). Microarray data was analyzed using GeneSpring GX (Agilent Technologies Inc., Santa Clara, CA). Selected genes were validated using qRT-PCR. Array data is deposited in ArrayExpress, accession number E-MEXP-2340.

**RNA interference.** Short interfering RNAs (siRNA) were transfected into cells using LipofectAMINE (Invitrogen) to concentrations as indicated. siRNAs were purchased from Eurogentec (Eurogentec, Ltd.), using previously described sequences for p53 (25) and MYCN (21). All experiments were performed in triplicate.

**Irradiation-induced DNA damage and caspase assays.** Cells were treated with 4 Gy of X-irradiation from a RS320 irradiation system (Gulmay Medical).
at the indicated times post-irradiation for protein analysis or caspase analysis. Experiments were performed in triplicate. Caspase-3/7 activity was measured using the Caspase-Glo 3/7 assay (Promega) according to the instructions of the manufacturer. Experiments were performed in triplicate.

**Chromatin immunoprecipitation.** Chromatin immunoprecipitation (ChIP) was performed as previously described (26), using 5 μg of anti-MYCn B8.48, anti-Max C-17, or IgG (all from Santa Cruz Biotechnology, Inc.) as a negative control. Samples were analyzed using SYBR Green quantitative PCR with specific primers. Nucleolin was used as a positive control. Experiments were performed in triplicate. All primer sequences are listed in Supplementary Information Table S1.

**Figure 3.** p53 mRNA and protein expression, and DNA binding and transcriptional activity in Tet21N cells. A, p53 mRNA (left) and protein expression (right) in the presence of MYCN (paired t test, \( P < 0.05 \)). B, p53 DNA-binding capacity (left; paired t test, \( P < 0.005 \)) and p53-dependent reporter gene activity (right; paired t test, \( P < 0.05 \)) in the presence of MYCN. The luciferase activity of the p53-dependent pGL3-P2 reporter construct was normalized to β-galactosidase activity of pCMV-β-galactosidase plasmid construct. C, bar chart showing higher mRNA expression of p53 target genes MDM2 and PUMA in the presence of MYCN (paired t test, \( P < 0.05 \)). D, Western blot (left) and densitometry analysis (right) normalized to actin showing higher protein expression of p53 target genes MDM2 and PUMA in the presence of MYCN (paired t test, \( P < 0.05 \)).
**Actinomycin D and cycloheximide treatment.** Tet21N MYCN+ and MYCN− cells were treated with either 1 μg/mL of actinomycin D (Sigma), or 25 μmol/L of cycloheximide (Calbiochem). Cells were harvested at the indicated times after actinomycin D treatment for qRT-PCR analysis of mRNA expression, and after cycloheximide treatment for protein expression. Experiments were performed in triplicate.

**Statistical analyses.** Statistical tests were performed using Minitab (Minitab, Inc.) or GraphPad Prism (GraphPad Software, Inc.). All statistical tests were two-sided. If the expected frequency of a χ² test was <5, Fisher’s exact test was performed using GraphPad Prism.

**Results**

**p53 protein expression is associated with MYCN amplification and expression in neuroblastoma tumors.** p53 expression, localization, and relationship with histology in this set of neuroblastoma tumors has been previously reported (12). p53 was found to be predominantly nuclear and expressed at high levels in undifferentiated and poorly differentiated neuroblastoma (Fig. 1A; ref. 12). MYCN expression was nuclear, heterogeneous, and expressed at higher levels in undifferentiated, poorly differentiated, and International Neuroblastoma Pathology Classification unfavorable histology tumors (Fig. 1A; data not shown). MYCN was not expressed in Schwannian stroma (Fig. 1A). MYCN expression was significantly higher in MYCN-amplified tumors as expected and only three non–MYCN-amplified tumors expressed MYCN detectable by immunohistochemistry (Fig. 1A and B; Table 1). Using the median labeling index for p53 and MYCN in all 82 tumors as a cutoff between positive and negative expression, increased p53 expression was significantly associated with MYCN amplification with two of the p53 antibodies used (Table 1; Fig. 1A and C), and with MYCN expression with all three p53 antibodies (Table 1; Fig. 1A and D). For p53DO-7, the median difference in labeling index between MYCN-amplified and nonamplified neuroblastoma was 8.6%, median p53DO-7 labeling indices were 6.7% for non–MYCN-amplified tumors and 13.5% for MYCN-amplified tumors (Fig. 1C).

**p53 protein expression correlates with MYCN expression in neuroblastoma cell lines.** p53 protein levels were analyzed in a panel of 10 p53 wild-type neuroblastoma cell lines, conditional MYCN expressing SHEP Tet21N cells, and two negative control cell lines, p53 mutant SKNBE2C and p53 null SAOS2 cells (Fig. 2A). Induced levels of MYCN in Tet21N MYCN+ cells were comparable with MYCN-amplified neuroblastoma cell lines (Fig. 2A). p53 expression was found to correlate with MYCN expression (P < 0.005, r = 0.7924, Spearman correlation; Fig. 2A and B), but not with MYCN amplification (data not shown).

To further investigate p53 expression in relation to MYCN expression, MYCN expression was inhibited using siRNA in p53 wild-type MYCN-amplified SMSKCNR and LAN5 cells. This led to decreased p53 protein (Fig. 2C) and mRNA expression (Fig. 2D) in both cell lines. At 24 hours after MYCN knockdown, LAN5 cells exhibited a ∼40% reduction in p53 mRNA expression (Fig. 2D) and a ∼50% reduction in p53 protein expression (P < 0.05, paired t test; Fig. 2C), whereas the SMSKCNR cell line exhibited a ∼30% (Fig. 2D) and ∼40% (Fig. 2C) reduction in p53 mRNA and protein expression, respectively.

**p53 expression, transcriptional activity, and induction of p53-regulated genes in SHEP Tet21N cells.** Tet21N MYCN+ cells were found to express significantly higher p53 mRNA (P < 0.05, paired t test; Fig. 3A) and protein (P < 0.05, paired t test; Figs. 2A and 3A) compared with Tet21N MYCN− cells. Consistent with higher p53 transcript and protein levels, Tet21N MYCN+ cells exhibited significantly greater p53 DNA-binding capacity (P < 0.005, paired t test) and transcriptional activity (P < 0.05, paired t test; Fig. 3B) in comparison with Tet21N MYCN− cells. Furthermore, higher mRNA (P < 0.05, paired t test; Fig. 3C) and protein (P < 0.05, paired t test; Fig. 3D) expression of two endogenous p53 target genes, MDM2 and PUMA, were observed in Tet21N MYCN+ cells compared with Tet21N MYCN− cells, confirming the results of the reporter gene and DNA binding assays, indicating that the accumulated p53 in Tet21N MYCN+ cells is transcriptionally active.

Modulation of MYCN expression in Tet21N cells by continuous culture in the presence of tetracycline for 2 weeks, followed by the removal of tetracycline from the growth medium, resulted in the induction of MYCN expression and showed that p53 mRNA (data not shown) and protein expression positively correlated with MYCN protein expression (P < 0.005, r = 0.8667, Spearman correlation; Fig. 4A), lending further support for MYCN regulation of p53 in this system.

To determine whether p53 is functional after DNA damage in Tet21N MYCN+−/− cells, cells were subjected to 4 Gy of X-irradiation and analyzed for the expression of p21WAF1 and MDM2. Following DNA damage, there was an increase in Ser15 phosphorylated p53 as well as induction of p53,
p53 is a direct target gene of MYCN. MYCN ChIP was performed in two MYCN-amplified neuroblastoma cell lines and the Tet21N system to determine whether MYCN can directly bind to an E-Box motif within the p53 promoter in vivo. It was found that MYCN binds directly to the noncanonical E-Box motif located close to the transcriptional start site of p53 in Tet21N MYCN+ cells (Fig. 5C) and MYCN-amplified neuroblastoma cell lines LAN5 (Fig. 5C) and SKNBE2C (Supplementary Fig. S2). As expected, no MYCN binding was observed in Tet21N MYCN− cells (Fig. 5C). MYCN binding to the E-Box within the nucleolin promoter in Tet21N MYCN+ cells was used as a positive control (Fig. 5C).

To confirm the functional regulation of p53 by MYCN, p53 reporter constructs incorporating the wild-type E-Box motif, CATGTG (pGL2-200 bp and pGL2-356 bp), or the mutated E-Box motif, CTGCAG (pGL2-Δ200 bp and pGL2-Δ356 bp)
were transfected into Tet21N MYCN+ and Tet21N MYCN− cells, and also cotransfected with the pCMV14-MYCN expression plasmid into parental SHEP cells. In line with the above ChIP data, p53 promoter constructs incorporating the wildcard-type E-Box motif exhibited significantly greater luciferase activity in the presence of MYCN (P < 0.05, paired t test; Fig. 5D) in Tet21N cells as well as in SHEP cells cotransfected with pCMV14-MYCN (P < 0.05, paired t test; Fig. 5D). Mutation of the E-Box motif led to significantly reduced luciferase activity (P < 0.05, paired t test) in Tet21N MYCN+ cells (Fig. 5D) as well as in SHEP cells cotransfected with pCMV14-MYCN (P < 0.05, paired t test; Fig. 5D).

Discussion

Like c-MYC, MYCN plays a paradoxical role in driving both cellular proliferation (27) and inducing apoptosis (28–30). This is observed histologically by a high mitosis-karyorrhexis index in both human MYCN-amplified neuroblastoma tumors (31–34) and MYCN transgenic mouse neuroblastoma tumors (35). In addition, in transgenic mouse tumors, we reported tingible body macrophages reflecting high levels of apoptosis within these tumors (35). Studies using MYCN-amplified cell lines, MYCN transgenic mouse tumors and ectopic MYCN expressing Tet21N cells have shown higher p53 levels in the presence of MYCN (21, 36, 37) and increased levels of apoptosis in response to chemotherapeutic agents (28, 38–40), and irradiation (21).

We and others have previously observed wild-type nuclear functional p53 accumulation in neuroblastoma cell lines (reviewed in ref. 10) and tumors (12). p53 has been shown to be a direct target gene of c-MYC, in which the p53 promoter has been reported to contain an E-Box–related sequence (CATGTG) through which the Myc gene family exert transcriptional activity (13, 14). We hypothesized that p53 accumulation in neuroblastoma is related to MYCN amplification and expression and that p53 is a direct transcriptional target of MYCN in neuroblastoma.

Here, we show that p53 protein expression correlates with MYCN protein expression in both primary neuroblastoma tumors and neuroblastoma cell lines. Using a regulatable MYCN expression system, p53 was found to be functional and exhibited greater transcriptional activity in the presence of MYCN leading to increased expression of several p53 target genes. Using quantitative MYCN ChIP, MYCN was found to bind directly to the noncanonical E-Box motif (CATGTG) within the p53 promoter in vivo, and using reporter gene assays, direct functional upregulation of transcription from the p53 promoter by MYCN was shown. Furthermore, deletion of this E-Box led to reduced transcriptional activity from the p53 promoter by MYCN. This data provides strong support to the model that this specific E-Box is responsible for MYCN-mediated regulation of p53. The binding of MYCN to an E-Box within the p53 promoter has very recently been reported using ChIP-chip arrays (7), however, this study did not include the functional upregulation of p53. Taken together, these findings provide an important and direct mechanism by which MYCN is able to sensitize cells for p53-mediated apoptosis.

Our data is both consistent with and provides a direct mechanism to account for previous studies which have shown that MYCN-amplified neuroblastoma tumors expressed significantly higher levels of p53 RNA in comparison with nonamplified tumors (7, 41, 42). It is also possible that the association of p53 with undifferentiated, highly proliferative neuroblastoma we previously reported is mediated through MYCN (12), and that MYCN may be involved in other studies linking p53 RNA expression with unfavorable neuroblastoma (43).

Our data is also in line with work in the TH-MYCN transgenic mouse model which showed that MYCN-driven tumor formation had higher penetrance and reduced latency in p53 haploinsufficient mice, and that chemotherapy-induced apoptosis was shown to be p53-dependent, in which apoptosis was significantly reduced in TH-MYCN p53+/− tumors compared with p53+/− tumors (40).

Mechanisms by which members of the Myc family induce apoptosis are not fully understood (reviewed in ref. 44). One mechanism is via p14ARF-mediated increased p53 expression, stability, and activity (45), although we have previously reported that SHEP cells are homozygously deleted for p14ARF (18), and this was further confirmed in the present study (data not shown). However, p14ARF might be involved in other neuroblastoma cell lines in addition, or instead of, direct regulation of the p53 gene shown in the present study.

MYCN and p53 are both expressed in the normal embryonic developing nervous system, during the phase of precursor cell expansion prior to the onset of differentiation. In the context of normal embryonic development, the present findings therefore provide a mechanism for MYCN-driven p53-dependent apoptosis, which may be important in eliminating any rapidly proliferating neuroblasts exposed to potential teratogens to prevent deregulated proliferation and aberrations during development.

Our findings might help to explain why neuroblastomas are initially chemosensitive; however, despite an initial response, more than half of all cases relapse with chemoresistant disease, suggesting that MYCN-amplified tumors eventually develop mechanisms to evade MYCN-driven apoptosis (reviewed in ref. 9). There is evidence from cell line studies that MYCN-amplified cell lines may circumvent MYCN-driven p53-dependent apoptosis by selecting for cells with aberrations in the p53/MDM2/p14ARF pathway. Analysis of neuroblastoma cell lines reported to date with aberrations in the p53/MDM2/p14ARF pathway show that 25 of 34 (74%) cell lines are MYCN-amplified (Supplementary Information, Table S4) and predominantly established following previous therapy at relapse (18), when abnormalities of the p53 pathway in neuroblastoma tumors have been previously reported (reviewed in ref. 10). A study examining the p53 pathway in relapsed MYCN-amplified neuroblastomas is warranted.

Further illustrating the complexity of the paradoxical role of MYCN in proliferation and apoptosis, MDM2, the critical negative regulator of p53, has previously been reported to be
a direct target of MYCN (46). In the present study, siRNA-mediated inhibition of p53 led to a decrease in MDM2 expression (data not shown), suggesting that increased expression of MDM2 in the presence of MYCN may also be dependent on the higher expression of p53 and not solely due to direct upregulation by MYCN.

In conclusion, this study provides several lines of evidence that p53 is a direct transcriptional target of MYCN in neuroblastoma and is likely to be a mechanism for MYCN-induced p53-dependent apoptosis. However, the various selection pressures on MYCN-amplified tumors either spontaneously or via chemotherapy may lead to selection for those cells that can evade apoptosis by various mechanisms which result in MYCN-amplified neuroblastoma progressing to become such a severe phenotype.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

28. Fuelda S, Lutz W, Schwab M, Debatin KM. MycN sensitizes...
p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma

Lindi Chen, Nunzio Iraci, Samuele Gherardi, et al.

Cancer Res Published OnlineFirst February 9, 2010.

Updated version Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-09-2598

Supplementary Material Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2010/02/08/0008-5472.CAN-09-2598.DC1

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.